



---

The supplemental unaudited historical combined financial information on the following pages presents adjusted “comparable” revenues for the combined company for BD’s 2016 and 2017 fiscal years, respectively, and BD’s first quarter of fiscal year 2018, by business segment, geographic region and market.

Adjusted comparable revenues is a financial measure (a “non-GAAP financial measure”) that differs from revenues presented in accordance with U.S. generally accepted accounting principles (“GAAP”). The adjusted comparable revenues assume the Bard acquisition occurred at the start of BD’s 2016 fiscal year and then further adjust for:

- the realignment of certain product lines from BD’s Medical segment to BD’s Interventional segment and the realignment of certain Bard product lines to the BD Medical segment;
- the realignment of Bard’s country reporting to align with BD’s existing presentation;
- divestitures of BD’s Respiratory Solutions, BD Simplest and spine businesses, and the pending divestiture of BD’s soft tissue core needle biopsy product line and Bard’s Aspira® product line of tunneled home drainage catheters and accessories;
- the reclassification of the Gore royalty previously reported by Bard as revenues; and
- the elimination of certain revenues recognized between BD and Bard as intercompany revenues.

The supplemental information also shows growth in adjusted comparable revenues from fiscal year 2016 to fiscal year 2017 and for the first quarter of fiscal year 2018 compared to the prior year period on a “foreign currency-neutral” basis to eliminate the impact of fluctuations in foreign currency exchange rates by comparing the results between periods as if exchange rates had remained constant period-over-period. We calculate constant currency information by converting local currency financial results to U.S. dollars using the prior-period foreign currency exchange rates. The constant currency information we present may not be comparable to similar measures reported by other companies.

The supplemental unaudited historical combined financial information does not include any adjustments to fully conform to the accounting policies of BD.

We believe that the measure of adjusted comparable revenues presented will facilitate comparisons of the results of the combined company to prior periods and helps investors understand management’s revenue guidance for the combined company for fiscal year 2018. The supplemental unaudited historical combined financial information has been prepared for illustrative purposes only, and is not necessarily indicative of the operating results or financial position that would have occurred if the Bard acquisition had been consummated on the date indicated, nor is the information necessarily indicative of the results of operations that may be expected for any future period or date. BD and Bard may have performed differently had they actually been combined during the periods presented and such differences may be material. The supplemental unaudited historical combined financial information should not be considered in isolation, or viewed as a replacement of, or superior to, results prepared in compliance with GAAP or any pro forma financial statements subsequently required by the rules and regulations of the Securities and Exchange Commission.



---

BD has revised its reportable business segments (currently BD Medical and BD Life Sciences) by (i) including a new third segment, BD Interventional, which includes the majority of Bard's product offerings and certain product offerings previously reported in BD's Medical Segment and (ii) including certain of Bard's product offerings under BD's existing Medical segment. Specifically,

**BD Interventional Segment:**

- The new Surgery unit within the BD Interventional Segment includes Bard's former Surgical Specialties Product Group (which includes hernia and soft tissue repair, biological grafts, biosurgery, and other surgical products). In addition, the new Surgery unit includes products (such as BD ChloraPrep™ surgical, certain infection prevention products, and V. Mueller™) that were previously reported in the former Medication and Procedural Solutions unit within the Medical Segment.
- The new Peripheral Intervention unit within the BD Interventional Segment includes Bard's former Vascular Product Group (which includes catheters, ports, chronic dialysis, feeding, vascular grafts, endovascular radiology, biopsy, drug coated balloons, stents, and other interventional products), as well as some products from Bard's former Oncology Product Group (such as ports). In addition, the new Peripheral Intervention unit includes products (such as drainage) that were previously reported in the former Medication and Procedural Solutions unit.
- The new Urology and Critical Care unit within the BD Interventional Segment includes the majority of Bard's former Urology Product Group (such as catheters, continence, urological specialties, cancer diagnostics and therapy, and other products).

**BD Medical Segment:**

- The new Medication Delivery Solutions unit within the BD Medical Segment includes the majority of BD's former Medication and Procedural Solutions unit. In addition, the new Medication Delivery Solutions unit includes products that were formerly reported within Bard's Oncology Product Group (such as PICCs, midlines, CVCs, acute dialysis, and ultrasonic imaging), as well as some products formerly reported within Bard's Urology Product Group.



**UNITED STATES COMBINED REVENUES BY BUSINESS SEGMENTS AND UNITS**

(Unaudited; Amounts in millions)

	FY2016					FY2017										FY2018		
	Q1	Q2	Q3	Q4	Full Year	% Change		% Change		% Change		% Change		Full Year	% Change	% Change		
						Q1	Reported	Q2	Reported	Q3	Reported	Q4	Reported			Q1	Reported	
<b><u>BD MEDICAL</u></b>																		
Medication Delivery Solutions	468	458	465	492	1,883	481	2.8%	488	6.5%	476	2.4%	491	-0.3%	1,935	2.8%	512	6.5%	
Medication Management Solutions	439	439	473	428	1,779	492	12.0%	464	5.6%	447	-5.5%	440	3.0%	1,843	3.6%	471	-4.3%	
Diabetes Care	134	125	127	135	521	144	7.2%	124	-0.7%	132	4.2%	147	8.7%	546	4.9%	146	1.3%	
Pharmaceutical Systems	63	81	98	85	328	62	-1.1%	76	-6.0%	93	-5.3%	96	12.9%	328	0.1%	54	-14.0%	
<b>TOTAL</b>	<b>1,104</b>	<b>1,104</b>	<b>1,162</b>	<b>1,140</b>	<b>4,510</b>	<b>1,179</b>	<b>6.8%</b>	<b>1,152</b>	<b>4.4%</b>	<b>1,147</b>	<b>-1.3%</b>	<b>1,174</b>	<b>3.0%</b>	<b>4,652</b>	<b>3.2%</b>	<b>1,182</b>	<b>0.3%</b>	
<b><u>BD LIFE SCIENCES</u></b>																		
Preanalytical Systems	178	175	180	182	715	176	-0.9%	185	6.0%	191	5.9%	189	3.9%	741	3.7%	184	4.6%	
Diagnostic Systems	149	156	142	153	600	154	3.5%	173	10.5%	145	2.1%	151	-1.6%	622	3.7%	167	8.0%	
Biosciences	98	110	106	119	433	107	8.5%	110	-0.2%	115	8.2%	123	3.7%	455	4.9%	108	1.7%	
<b>TOTAL</b>	<b>425</b>	<b>441</b>	<b>428</b>	<b>454</b>	<b>1,748</b>	<b>437</b>	<b>2.8%</b>	<b>467</b>	<b>6.0%</b>	<b>451</b>	<b>5.2%</b>	<b>463</b>	<b>2.0%</b>	<b>1,818</b>	<b>4.0%</b>	<b>459</b>	<b>5.1%</b>	
<b><u>BD INTERVENTIONAL</u></b>																		
Surgery	260	265	254	267	1,047	266	2.3%	267	0.8%	262	3.1%	256	-4.4%	1,051	0.4%	247	-7.3%	
Peripheral Intervention	165	169	172	175	682	175	6.0%	175	3.0%	181	5.3%	187	7.1%	718	5.4%	193	9.8%	
Urology and Critical Care	149	160	162	165	635	174	17.2%	169	5.5%	167	3.2%	172	3.9%	681	7.2%	177	1.5%	
<b>TOTAL</b>	<b>575</b>	<b>594</b>	<b>588</b>	<b>607</b>	<b>2,364</b>	<b>616</b>	<b>7.2%</b>	<b>610</b>	<b>2.7%</b>	<b>610</b>	<b>3.8%</b>	<b>614</b>	<b>1.2%</b>	<b>2,451</b>	<b>3.7%</b>	<b>617</b>	<b>0.1%</b>	
<b>TOTAL UNITED STATES</b>	<b>2,104</b>	<b>2,139</b>	<b>2,178</b>	<b>2,201</b>	<b>8,622</b>	<b>2,232</b>	<b>6.1%</b>	<b>2,230</b>	<b>4.3%</b>	<b>2,208</b>	<b>1.4%</b>	<b>2,251</b>	<b>2.3%</b>	<b>8,921</b>	<b>3.5%</b>	<b>2,258</b>	<b>1.2%</b>	

**INTERNATIONAL COMBINED REVENUES BY BUSINESS SEGMENTS AND UNITS**

(Unaudited; Amounts in millions)

	FY2016					FY2017																FY2018											
	Q1	Q2	Q3	Q4	Full Year	% Change				% Change				% Change				% Change				% Change											
						Q1	Reported	FXN	FX Impact	Q2	Reported	FXN	FX Impact	Q3	Reported	FXN	FX Impact	Q4	Reported	FXN	FX Impact	Full Year	Reported	FXN	FX Impact	Q1	Reported	FXN	FX Impact				
<b>BD MEDICAL</b>																																	
Medication Delivery Solutions	382	370	405	401	1,559	406	6.2%	8.3%	-2.0%	397	7.2%	8.7%	-1.6%	426	5.2%	7.8%	-2.6%	434	8.2%	7.9%	0.3%	1,663	6.7%	8.1%	-1.5%	440	8.4%	5.0%	3.4%				
Medication Management Solutions	106	94	112	107	419	109	2.9%	6.9%	-4.1%	103	9.6%	13.6%	-4.0%	109	-3.0%	1.0%	-4.0%	131	22.9%	21.5%	1.4%	452	7.9%	10.6%	-2.7%	116	6.5%	0.6%	5.9%				
Diabetes Care	121	118	132	131	502	124	1.8%	1.6%	0.2%	119	0.7%	1.7%	-1.0%	131	-0.7%	1.2%	-1.9%	136	4.4%	4.1%	0.3%	510	1.6%	2.2%	-0.6%	132	6.4%	3.2%	3.2%				
Pharmaceutical Systems	133	229	244	265	872	165	23.5%	23.3%	0.2%	235	2.6%	5.6%	-3.0%	258	5.6%	7.5%	-1.9%	271	2.3%	0.4%	1.9%	929	6.6%	7.3%	-0.7%	192	16.4%	10.4%	6.0%				
<b>TOTAL</b>	<b>743</b>	<b>812</b>	<b>893</b>	<b>903</b>	<b>3,351</b>	<b>804</b>	<b>8.1%</b>	<b>9.7%</b>	<b>-1.6%</b>	<b>854</b>	<b>5.2%</b>	<b>7.4%</b>	<b>-2.2%</b>	<b>923</b>	<b>3.4%</b>	<b>5.9%</b>	<b>-2.5%</b>	<b>972</b>	<b>7.6%</b>	<b>6.7%</b>	<b>0.9%</b>	<b>3,553</b>	<b>6.0%</b>	<b>7.3%</b>	<b>-1.3%</b>	<b>880</b>	<b>9.5%</b>	<b>5.2%</b>	<b>4.2%</b>				
<b>BD LIFE SCIENCES</b>																																	
Preanalytical Systems	166	165	186	177	694	179	7.8%	9.7%	-1.9%	177	7.1%	9.1%	-2.0%	185	-0.5%	2.0%	-2.5%	189	6.8%	6.8%	0.0%	730	5.2%	6.8%	-1.6%	191	6.6%	3.4%	3.2%				
Diagnostic Systems	164	163	185	189	701	179	9.1%	9.1%	0.0%	178	9.2%	10.6%	-1.4%	191	3.0%	5.0%	-2.0%	208	10.5%	10.7%	-0.3%	756	7.9%	8.8%	-0.9%	214	19.4%	16.2%	3.1%				
Biosciences	177	167	164	177	685	163	-8.1%	-7.4%	-0.7%	160	-4.5%	-2.9%	-1.6%	171	4.2%	6.4%	-2.2%	191	7.7%	7.3%	0.4%	684	-0.2%	0.8%	-1.0%	181	11.0%	7.8%	3.3%				
<b>TOTAL</b>	<b>508</b>	<b>495</b>	<b>535</b>	<b>542</b>	<b>2,080</b>	<b>521</b>	<b>2.7%</b>	<b>3.5%</b>	<b>-0.9%</b>	<b>514</b>	<b>3.9%</b>	<b>5.6%</b>	<b>-1.7%</b>	<b>547</b>	<b>2.2%</b>	<b>4.4%</b>	<b>-2.2%</b>	<b>588</b>	<b>8.4%</b>	<b>8.3%</b>	<b>0.1%</b>	<b>2,170</b>	<b>4.3%</b>	<b>5.5%</b>	<b>-1.2%</b>	<b>586</b>	<b>12.4%</b>	<b>9.2%</b>	<b>3.2%</b>				
<b>BD INTERVENTIONAL</b>																																	
Surgery	50	50	60	58	218	62	23.2%	28.2%	-5.0%	58	15.8%	20.3%	-4.5%	64	6.0%	10.7%	-4.7%	63	8.5%	9.1%	-0.6%	247	12.9%	16.5%	-3.7%	71	14.7%	10.2%	4.5%				
Peripheral Intervention	111	110	124	123	468	127	14.6%	15.2%	-0.6%	120	8.8%	11.0%	-2.2%	136	9.1%	12.4%	-3.3%	138	12.1%	11.8%	0.3%	521	11.1%	12.6%	-1.4%	147	15.9%	12.0%	3.9%				
Urology and Critical Care	74	62	82	82	299	87	17.5%	19.1%	-1.6%	73	18.5%	22.5%	-4.0%	80	-3.2%	1.5%	-4.7%	81	-0.8%	1.9%	-2.7%	320	7.0%	10.3%	-3.2%	90	4.4%	2.3%	2.1%				
<b>TOTAL</b>	<b>235</b>	<b>222</b>	<b>267</b>	<b>263</b>	<b>986</b>	<b>276</b>	<b>17.4%</b>	<b>19.2%</b>	<b>-1.9%</b>	<b>251</b>	<b>13.1%</b>	<b>16.3%</b>	<b>-3.2%</b>	<b>279</b>	<b>4.6%</b>	<b>8.7%</b>	<b>-4.1%</b>	<b>282</b>	<b>7.3%</b>	<b>8.2%</b>	<b>-0.8%</b>	<b>1,088</b>	<b>10.3%</b>	<b>12.8%</b>	<b>-2.5%</b>	<b>309</b>	<b>12.0%</b>	<b>8.6%</b>	<b>3.4%</b>				
<b>TOTAL INTERNATIONAL</b>	<b>1,486</b>	<b>1,529</b>	<b>1,694</b>	<b>1,708</b>	<b>6,418</b>	<b>1,600</b>	<b>7.7%</b>	<b>9.1%</b>	<b>-1.4%</b>	<b>1,620</b>	<b>5.9%</b>	<b>8.1%</b>	<b>-2.2%</b>	<b>1,749</b>	<b>3.2%</b>	<b>5.9%</b>	<b>-2.7%</b>	<b>1,842</b>	<b>7.8%</b>	<b>7.5%</b>	<b>0.4%</b>	<b>6,811</b>	<b>6.1%</b>	<b>7.6%</b>	<b>-1.4%</b>	<b>1,774</b>	<b>10.9%</b>	<b>7.1%</b>	<b>3.8%</b>				



**WORLDWIDE COMBINED REVENUES BY MARKET CLASSIFICATION AND CHINA**

(Unaudited; Amounts in millions)

	FY2016					FY2017													FY2018										
	Q1	Q2	Q3	Q4	Full Year	% Change			% Change			% Change			% Change			Full Year	% Change			% Change							
						Q1	Reported	FXN	FX Impact	Q2	Reported	FXN	FX Impact	Q3	Reported	FXN	FX Impact		Q4	Reported	FXN	FX Impact	Q1	Reported	FXN	FX Impact			
EMERGING MARKETS	516	495	549	572	2,132	551	6.9%	10.2%	-3.3%	539	8.8%	10.1%	-1.3%	610	11.1%	13.1%	-2.1%	652	14.0%	14.2%	-0.2%	2,352	10.3%	12.0%	-1.7%	626	13.6%	11.9%	1.7%
DEVELOPED MARKETS	3,074	3,173	3,324	3,338	12,908	3,281	6.7%	6.9%	-0.1%	3,311	4.4%	5.2%	-0.8%	3,347	0.7%	1.7%	-1.0%	3,441	3.1%	2.9%	0.2%	13,380	3.7%	4.1%	-0.4%	3,406	3.8%	2.3%	1.5%
CHINA	206	207	222	219	855	220	6.4%	12.6%	-6.2%	223	7.7%	13.1%	-5.5%	245	10.2%	15.7%	-5.5%	252	15.2%	16.3%	-1.1%	940	9.9%	14.5%	-4.6%	252	14.9%	12.4%	2.6%

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended December 31, 2015</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	491	(148)	-	135	0	(7)	-	(3)	468
Medication Management Solutions	439	-	-	-	-	-	-	-	439
Diabetes Care	134	-	-	-	-	-	-	-	134
Pharmaceutical Systems	63	-	-	-	-	-	-	-	63
Respiratory Solutions	139	-	-	-	-	(139)	-	-	-
<b>TOTAL</b>	<b>1,266</b>	<b>(148)</b>	<b>-</b>	<b>135</b>	<b>0</b>	<b>(146)</b>	<b>-</b>	<b>(3)</b>	<b>1,104</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	178	-	-	-	-	-	-	-	178
Diagnostic Systems	149	-	-	-	-	-	-	-	149
Biosciences	98	-	-	-	-	-	-	-	98
<b>TOTAL</b>	<b>425</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>425</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	145	-	124	0	(9)	-	(0)	260
Peripheral Intervention	-	4	-	198	1	-	(38)	-	165
Urology and Critical Care	-	-	-	149	0	-	-	-	149
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	154	(154)	-	-	-	-	-
<i>Urology</i>	-	-	149	(149)	-	-	-	-	-
<i>Oncology</i>	-	-	168	(168)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	120	(120)	-	-	-	-	-
<i>Other</i>	-	-	15	(15)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>148</b>	<b>606</b>	<b>(135)</b>	<b>1</b>	<b>(9)</b>	<b>(38)</b>	<b>(0)</b>	<b>575</b>
<b>TOTAL UNITED STATES</b>	<b>1,691</b>	<b>(0)</b>	<b>606</b>	<b>-</b>	<b>2</b>	<b>(155)</b>	<b>(38)</b>	<b>(3)</b>	<b>2,104</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended March 31, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	484	(155)	-	138	0	(6)	-	(3)	458
Medication Management Solutions	439	-	-	-	-	-	-	-	439
Diabetes Care	125	-	-	-	-	-	-	-	125
Pharmaceutical Systems	81	-	-	-	-	-	-	-	81
Respiratory Solutions	149	-	-	-	-	(149)	-	-	-
<b>TOTAL</b>	<b>1,278</b>	<b>(155)</b>	<b>-</b>	<b>138</b>	<b>0</b>	<b>(155)</b>	<b>-</b>	<b>(3)</b>	<b>1,104</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	175	-	-	-	-	-	-	-	175
Diagnostic Systems	156	-	-	-	-	-	-	-	156
Biosciences	110	-	-	-	-	-	-	-	110
<b>TOTAL</b>	<b>441</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>441</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	151	-	123	0	(10)	-	(0)	265
Peripheral Intervention	-	4	-	204	1	-	(38)	-	169
Urology and Critical Care	-	-	-	160	0	-	-	-	160
<i>Legacy Bard Product Groups</i>									
Vascular	-	-	156	(156)	-	-	-	-	-
Urology	-	-	159	(159)	-	-	-	-	-
Oncology	-	-	173	(173)	-	-	-	-	-
Surgical Specialties	-	-	119	(119)	-	-	-	-	-
Other	-	-	17	(17)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>155</b>	<b>625</b>	<b>(138)</b>	<b>1</b>	<b>(10)</b>	<b>(38)</b>	<b>(0)</b>	<b>594</b>
<b>TOTAL UNITED STATES</b>	<b>1,719</b>	<b>(0)</b>	<b>625</b>	<b>-</b>	<b>1</b>	<b>(165)</b>	<b>(38)</b>	<b>(3)</b>	<b>2,139</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended June 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	473	(143)	-	140	0	(3)	-	(4)	465
Medication Management Solutions	473	-	-	-	-	-	-	-	473
Diabetes Care	127	-	-	-	-	-	-	-	127
Pharmaceutical Systems	98	-	-	-	-	-	-	-	98
Respiratory Solutions	136	-	-	-	-	(136)	-	-	-
<b>TOTAL</b>	<b>1,307</b>	<b>(143)</b>	<b>-</b>	<b>140</b>	<b>0</b>	<b>(139)</b>	<b>-</b>	<b>(4)</b>	<b>1,162</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	180	-	-	-	-	-	-	-	180
Diagnostic Systems	142	-	-	-	-	-	-	-	142
Biosciences	106	-	-	-	-	-	-	-	106
<b>TOTAL</b>	<b>428</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>428</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	139	-	124	0	(9)	-	(0)	254
Peripheral Intervention	-	4	-	207	1	-	(39)	-	172
Urology and Critical Care	-	-	-	161	0	-	-	-	162
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	161	(161)	-	-	-	-	-
<i>Urology</i>	-	-	163	(163)	-	-	-	-	-
<i>Oncology</i>	-	-	173	(173)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	120	(120)	-	-	-	-	-
<i>Other</i>	-	-	17	(17)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>143</b>	<b>633</b>	<b>(140)</b>	<b>1</b>	<b>(9)</b>	<b>(39)</b>	<b>(0)</b>	<b>588</b>
<b>TOTAL UNITED STATES</b>	<b>1,735</b>	<b>(0)</b>	<b>633</b>	<b>-</b>	<b>2</b>	<b>(148)</b>	<b>(39)</b>	<b>(4)</b>	<b>2,178</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended September 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	511	(154)	-	142	0	(3)	-	(4)	492
Medication Management Solutions	428	-	-	-	-	-	-	-	428
Diabetes Care	135	-	-	-	-	-	-	-	135
Pharmaceutical Systems	85	-	-	-	-	-	-	-	85
Respiratory Solutions	135	-	-	-	-	(135)	-	-	-
<b>TOTAL</b>	<b>1,294</b>	<b>(154)</b>	<b>-</b>	<b>142</b>	<b>0</b>	<b>(138)</b>	<b>-</b>	<b>(4)</b>	<b>1,140</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	182	-	-	-	-	-	-	-	182
Diagnostic Systems	153	-	-	-	-	-	-	-	153
Biosciences	119	-	-	-	-	-	-	-	119
<b>TOTAL</b>	<b>454</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>454</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	150	-	126	0	(10)	-	(0)	267
Peripheral Intervention	-	4	-	213	1	-	(43)	-	175
Urology and Critical Care	-	-	-	165	0	-	-	-	165
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	166	(166)	-	-	-	-	-
<i>Urology</i>	-	-	165	(165)	-	-	-	-	-
<i>Oncology</i>	-	-	177	(177)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	121	(121)	-	-	-	-	-
<i>Other</i>	-	-	17	(17)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>154</b>	<b>646</b>	<b>(142)</b>	<b>1</b>	<b>(10)</b>	<b>(43)</b>	<b>(0)</b>	<b>607</b>
<b>TOTAL UNITED STATES</b>	<b>1,748</b>	<b>0</b>	<b>646</b>	<b>-</b>	<b>2</b>	<b>(148)</b>	<b>(43)</b>	<b>(4)</b>	<b>2,201</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>12 Months Ended September 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	1,959	(599)	-	556	1	(19)	-	(14)	1,883
Medication Management Solutions	1,779	-	-	-	-	-	-	-	1,779
Diabetes Care	521	-	-	-	-	-	-	-	521
Pharmaceutical Systems	328	-	-	-	-	-	-	-	328
Respiratory Solutions	559	-	-	-	-	(559)	-	-	-
<b>TOTAL</b>	<b>5,144</b>	<b>(599)</b>	<b>-</b>	<b>556</b>	<b>1</b>	<b>(578)</b>	<b>-</b>	<b>(14)</b>	<b>4,510</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	715	-	-	-	-	-	-	-	715
Diagnostic Systems	600	-	-	-	-	-	-	-	600
Biosciences	433	-	-	-	-	-	-	-	433
<b>TOTAL</b>	<b>1,748</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,748</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	585	-	498	2	(37)	-	(0)	1,047
Peripheral Intervention	-	14	-	822	3	-	(158)	-	682
Urology and Critical Care	-	-	-	635	1	-	-	-	635
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	637	(637)	-	-	-	-	-
<i>Urology</i>	-	-	636	(636)	-	-	-	-	-
<i>Oncology</i>	-	-	691	(691)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	480	(480)	-	-	-	-	-
<i>Other</i>	-	-	67	(67)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>599</b>	<b>2,511</b>	<b>(556)</b>	<b>5</b>	<b>(37)</b>	<b>(158)</b>	<b>(0)</b>	<b>2,364</b>
<b>TOTAL UNITED STATES</b>	<b>6,893</b>	<b>0</b>	<b>2,511</b>	<b>-</b>	<b>6</b>	<b>(615)</b>	<b>(158)</b>	<b>(14)</b>	<b>8,622</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	Comparable Period	Reported % Change
<b>3 Months Ended December 31, 2016</b>											
<b>BD MEDICAL</b>											
Medication Delivery Solutions (previously Medication and Procedural Solutions)	495	(149)	-	139	0	-	-	(4)	481	468	2.8%
Medication Management Solutions	492	-	-	-	-	-	-	-	492	439	12.0%
Diabetes Care	144	-	-	-	-	-	-	-	144	134	7.2%
Pharmaceutical Systems	62	-	-	-	-	-	-	-	62	63	-1.1%
Respiratory Solutions	-	-	-	-	-	-	-	-	-	-	NM
<b>TOTAL</b>	<b>1,193</b>	<b>(149)</b>	<b>-</b>	<b>139</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>(4)</b>	<b>1,179</b>	<b>1,104</b>	<b>6.8%</b>
<b>BD LIFE SCIENCES</b>											
Preanalytical Systems	176	-	-	-	-	-	-	-	176	178	-0.9%
Diagnostic Systems	154	-	-	-	-	-	-	-	154	149	3.5%
Biosciences	107	-	-	-	-	-	-	-	107	98	8.5%
<b>TOTAL</b>	<b>437</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>437</b>	<b>425</b>	<b>2.8%</b>
<b>BD INTERVENTIONAL</b>											
Surgery	-	146	-	130	1	(10)	-	(0)	266	260	2.3%
Peripheral Intervention	-	3	-	212	1	-	(41)	-	175	165	6.0%
Urology and Critical Care	-	-	-	174	0	-	-	-	174	149	17.2%
<i>Legacy Bard Product Groups</i>											
<i>Vascular</i>	-	-	165	(165)	-	-	-	-	-	-	-
<i>Urology</i>	-	-	171	(171)	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	175	(175)	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	125	(125)	-	-	-	-	-	-	-
<i>Other</i>	-	-	18	(18)	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>149</b>	<b>655</b>	<b>(139)</b>	<b>1</b>	<b>(10)</b>	<b>(41)</b>	<b>(0)</b>	<b>616</b>	<b>575</b>	<b>7.2%</b>
<b>TOTAL UNITED STATES</b>	<b>1,630</b>	<b>(0)</b>	<b>655</b>	<b>-</b>	<b>2</b>	<b>(10)</b>	<b>(41)</b>	<b>(4)</b>	<b>2,232</b>	<b>2,104</b>	<b>6.1%</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	Comparable Period	Reported % Change
<b>3 Months Ended March 31, 2017</b>											
<b>BD MEDICAL</b>											
Medication Delivery Solutions (previously Medication and Procedural Solutions)	495	(150)	-	146	0	-	-	(4)	488	458	6.5%
Medication Management Solutions	464	-	-	-	-	-	-	-	464	439	5.6%
Diabetes Care	124	-	-	-	-	-	-	-	124	125	-0.7%
Pharmaceutical Systems	76	-	-	-	-	-	-	-	76	81	-6.0%
Respiratory Solutions	-	-	-	-	-	-	-	-	-	-	NM
<b>TOTAL</b>	<b>1,159</b>	<b>(150)</b>	<b>-</b>	<b>146</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>(4)</b>	<b>1,152</b>	<b>1,104</b>	<b>4.4%</b>
<b>BD LIFE SCIENCES</b>											
Preanalytical Systems	185	-	-	-	-	-	-	-	185	175	6.0%
Diagnostic Systems	173	-	-	-	-	-	-	-	173	156	10.5%
Biosciences	110	-	-	-	-	-	-	-	110	110	-0.2%
<b>TOTAL</b>	<b>467</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>467</b>	<b>441</b>	<b>6.0%</b>
<b>BD INTERVENTIONAL</b>											
Surgery	-	146	-	130	0	(10)	-	(0)	267	265	0.8%
Peripheral Intervention	-	4	-	212	1	-	(42)	-	175	169	3.0%
Urology and Critical Care	-	-	-	168	0	-	-	-	169	160	5.5%
<i>Legacy Bard Product Groups</i>											
<i>Vascular</i>	-	-	165	(165)	-	-	-	-	-	-	-
<i>Urology</i>	-	-	168	(168)	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	181	(181)	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	125	(125)	-	-	-	-	-	-	-
<i>Other</i>	-	-	18	(18)	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>150</b>	<b>657</b>	<b>(146)</b>	<b>1</b>	<b>(10)</b>	<b>(42)</b>	<b>(0)</b>	<b>610</b>	<b>594</b>	<b>2.7%</b>
<b>TOTAL UNITED STATES</b>	<b>1,627</b>	<b>0</b>	<b>657</b>	<b>-</b>	<b>1</b>	<b>(10)</b>	<b>(42)</b>	<b>(4)</b>	<b>2,230</b>	<b>2,139</b>	<b>4.3%</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	Comparable Period	Reported % Change
<b>3 Months Ended June 30, 2017</b>											
<b>BD MEDICAL</b>											
Medication Delivery Solutions (previously Medication and Procedural Solutions)	480	(145)	-	144	0	-	-	(3)	476	465	2.4%
Medication Management Solutions	447	-	-	-	-	-	-	-	447	473	-5.5%
Diabetes Care	132	-	-	-	-	-	-	-	132	127	4.2%
Pharmaceutical Systems	93	-	-	-	-	-	-	-	93	98	-5.3%
Respiratory Solutions	(0)	-	-	-	-	0	-	-	-	-	NM
<b>TOTAL</b>	<b>1,152</b>	<b>(145)</b>	<b>-</b>	<b>144</b>	<b>0</b>	<b>0</b>	<b>-</b>	<b>(3)</b>	<b>1,147</b>	<b>1,162</b>	<b>-1.3%</b>
<b>BD LIFE SCIENCES</b>											
Preamerical Systems	191	-	-	-	-	-	-	-	191	180	5.9%
Diagnostic Systems	145	-	-	-	-	-	-	-	145	142	2.1%
Biosciences	115	-	-	-	-	-	-	-	115	106	8.2%
<b>TOTAL</b>	<b>451</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>451</b>	<b>428</b>	<b>5.2%</b>
<b>BD INTERVENTIONAL</b>											
Surgery	-	142	-	129	1	(9)	-	(0)	262	254	3.1%
Peripheral Intervention	-	3	-	221	1	-	(44)	-	181	172	5.3%
Urology and Critical Care	-	-	-	167	0	-	-	-	167	162	3.2%
<i>Legacy Bard Product Groups</i>											
Vascular	-	-	173	(173)	-	-	-	-	-	-	-
Urology	-	-	166	(166)	-	-	-	-	-	-	-
Oncology	-	-	179	(179)	-	-	-	-	-	-	-
Surgical Specialties	-	-	124	(124)	-	-	-	-	-	-	-
Other	-	-	18	(18)	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>145</b>	<b>660</b>	<b>(144)</b>	<b>2</b>	<b>(9)</b>	<b>(44)</b>	<b>(0)</b>	<b>610</b>	<b>588</b>	<b>3.8%</b>
<b>TOTAL UNITED STATES</b>	<b>1,603</b>	<b>0</b>	<b>660</b>	<b>-</b>	<b>2</b>	<b>(9)</b>	<b>(44)</b>	<b>(3)</b>	<b>2,208</b>	<b>2,178</b>	<b>1.4%</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	Comparable Period	Reported % Change
<b>3 Months Ended September 30, 2017</b>											
<b>BD MEDICAL</b>											
Medication Delivery Solutions (previously Medication and Procedural Solutions)	498	(146)	-	142	0	-	-	(3)	491	492	-0.3%
Medication Management Solutions	440	-	-	-	-	-	-	-	440	428	3.0%
Diabetes Care	147	-	-	-	-	-	-	-	147	135	8.7%
Pharmaceutical Systems	96	-	-	-	-	-	-	-	96	85	12.9%
Respiratory Solutions	-	-	-	-	-	-	-	-	-	-	NM
<b>TOTAL</b>	<b>1,181</b>	<b>(146)</b>	<b>-</b>	<b>142</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>(3)</b>	<b>1,174</b>	<b>1,140</b>	<b>3.0%</b>
<b>BD LIFE SCIENCES</b>											
Preanalytical Systems	189	-	-	-	-	-	-	-	189	182	3.9%
Diagnostic Systems	151	-	-	-	-	-	-	-	151	153	-1.6%
Biosciences	123	-	-	-	-	-	-	-	123	119	3.7%
<b>TOTAL</b>	<b>463</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>463</b>	<b>454</b>	<b>2.0%</b>
<b>BD INTERVENTIONAL</b>											
Surgery	-	143	-	122	0	(10)	-	(0)	256	267	-4.4%
Peripheral Intervention	-	3	-	230	1	-	(47)	-	187	175	7.1%
Urology and Critical Care	-	-	-	171	0	-	-	-	172	165	3.9%
<i>Legacy Bard Product Groups</i>											
<i>Vascular</i>	-	-	184	(184)	-	-	-	-	-	-	-
<i>Urology</i>	-	-	171	(171)	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	178	(178)	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	116	(116)	-	-	-	-	-	-	-
<i>Other</i>	-	-	17	(17)	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>146</b>	<b>666</b>	<b>(142)</b>	<b>1</b>	<b>(10)</b>	<b>(47)</b>	<b>(0)</b>	<b>614</b>	<b>607</b>	<b>1.2%</b>
<b>TOTAL UNITED STATES</b>	<b>1,644</b>	<b>(0)</b>	<b>666</b>	<b>-</b>	<b>1</b>	<b>(10)</b>	<b>(47)</b>	<b>(4)</b>	<b>2,251</b>	<b>2,201</b>	<b>2.3%</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	Comparable Period	Reported % Change
<b>12 Months Ended September 30, 2017</b>											
<b>BD MEDICAL</b>											
Medication Delivery Solutions (previously Medication and Procedural Solutions)	1,968	(591)	-	571	1	-	-	(14)	1,935	1,883	2.8%
Medication Management Solutions	1,843	-	-	-	-	-	-	-	1,843	1,779	3.6%
Diabetes Care	546	-	-	-	-	-	-	-	546	521	4.9%
Pharmaceutical Systems	328	-	-	-	-	-	-	-	328	328	0.1%
Respiratory Solutions	(0)	-	-	-	-	0	-	-	-	-	NM
<b>TOTAL</b>	<b>4,685</b>	<b>(591)</b>	<b>-</b>	<b>571</b>	<b>1</b>	<b>0</b>	<b>-</b>	<b>(14)</b>	<b>4,652</b>	<b>4,510</b>	<b>3.2%</b>
<b>BD LIFE SCIENCES</b>											
Preanalytical Systems	741	-	-	-	-	-	-	-	741	715	3.7%
Diagnostic Systems	622	-	-	-	-	-	-	-	622	600	3.7%
Biosciences	455	-	-	-	-	-	-	-	455	433	4.9%
<b>TOTAL</b>	<b>1,818</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,818</b>	<b>1,748</b>	<b>4.0%</b>
<b>BD INTERVENTIONAL</b>											
Surgery	-	577	-	511	2	(39)	-	(0)	1,051	1,047	0.4%
Peripheral Intervention	-	14	-	875	3	-	(173)	-	718	682	5.4%
Urology and Critical Care	-	-	-	681	0	-	-	-	681	635	7.2%
<i>Legacy Bard Product Groups</i>											
<i>Vascular</i>	-	-	687	(687)	-	-	-	-	-	-	-
<i>Urology</i>	-	-	676	(676)	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	714	(714)	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	491	(491)	-	-	-	-	-	-	-
<i>Other</i>	-	-	71	(71)	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>591</b>	<b>2,638</b>	<b>(571)</b>	<b>5</b>	<b>(39)</b>	<b>(173)</b>	<b>(0)</b>	<b>2,451</b>	<b>2,364</b>	<b>3.7%</b>
<b>TOTAL UNITED STATES</b>	<b>6,504</b>	<b>0</b>	<b>2,638</b>	<b>-</b>	<b>6</b>	<b>(39)</b>	<b>(173)</b>	<b>(14)</b>	<b>8,921</b>	<b>8,622</b>	<b>3.5%</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - UNITED STATES  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	Comparable Period	Reported % Change
<b>3 Months Ended December 31, 2017</b>											
<b>BD MEDICAL</b>											
Medication Delivery Solutions (previously Medication and Procedural Solutions)	527	(157)	-	145	0	-	-	(3)	512	481	6.5%
Medication Management Solutions	471	-	-	-	-	-	-	-	471	492	-4.3%
Diabetes Care	146	-	-	-	-	-	-	-	146	144	1.3%
Pharmaceutical Systems	54	-	-	-	-	-	-	-	54	62	-14.0%
Respiratory Solutions	0	-	-	-	-	(0)	-	-	-	-	NM
<b>TOTAL</b>	<b>1,197</b>	<b>(157)</b>	<b>-</b>	<b>145</b>	<b>0</b>	<b>(0)</b>	<b>-</b>	<b>(3)</b>	<b>1,182</b>	<b>1,179</b>	<b>0.3%</b>
<b>BD LIFE SCIENCES</b>											
Preanalytical Systems	184	-	-	-	-	-	-	-	184	176	4.6%
Diagnostic Systems	167	-	-	-	-	-	-	-	167	154	8.0%
Biosciences	108	-	-	-	-	-	-	-	108	107	1.7%
<b>TOTAL</b>	<b>459</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>459</b>	<b>437</b>	<b>5.1%</b>
<b>BD INTERVENTIONAL</b>											
Surgery	-	152	-	104	0	(10)	-	(0)	247	266	-7.3%
Peripheral Intervention	-	5	-	233	1	-	(46)	-	193	175	9.8%
Urology and Critical Care	-	-	-	177	0	-	-	-	177	174	1.5%
<i>Legacy Bard Product Groups</i>											
Vascular	-	-	185	(185)	-	-	-	-	-	-	-
Urology	-	-	176	(176)	-	-	-	-	-	-	-
Oncology	-	-	180	(180)	-	-	-	-	-	-	-
Surgical Specialties	-	-	100	(100)	-	-	-	-	-	-	-
Other	-	-	19	(19)	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>157</b>	<b>659</b>	<b>(145)</b>	<b>1</b>	<b>(10)</b>	<b>(46)</b>	<b>(0)</b>	<b>617</b>	<b>616</b>	<b>0.1%</b>
<b>TOTAL UNITED STATES</b>	<b>1,657</b>	<b>0</b>	<b>659</b>	<b>-</b>	<b>2</b>	<b>(10)</b>	<b>(46)</b>	<b>(3)</b>	<b>2,258</b>	<b>2,232</b>	<b>1.2%</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended December 31, 2015</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	357	(22)	-	47	(0)	-	-	-	382
Medication Management Solutions	106	-	-	-	-	-	-	-	106
Diabetes Care	121	0	-	-	-	-	-	-	121
Pharmaceutical Systems	133	-	-	-	-	-	-	-	133
Respiratory Solutions	69	-	-	-	-	(69)	-	-	-
<b>TOTAL</b>	<b>788</b>	<b>(22)</b>	<b>-</b>	<b>47</b>	<b>(0)</b>	<b>(69)</b>	<b>-</b>	<b>-</b>	<b>743</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	166	-	-	-	-	-	-	-	166
Diagnostic Systems	164	-	-	-	-	-	-	-	164
Biosciences	177	-	-	-	-	-	-	-	177
<b>TOTAL</b>	<b>508</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>508</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	21	-	33	(0)	(3)	-	-	50
Peripheral Intervention	-	1	-	111	(1)	-	-	-	111
Urology and Critical Care	-	-	-	74	(0)	-	-	-	74
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	85	(85)	-	-	-	-	-
<i>Urology</i>	-	-	69	(69)	-	-	-	-	-
<i>Oncology</i>	-	-	69	(69)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	33	(33)	-	-	-	-	-
<i>Other</i>	-	-	8	(8)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>22</b>	<b>264</b>	<b>(47)</b>	<b>(1)</b>	<b>(3)</b>	<b>-</b>	<b>-</b>	<b>235</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,295</b>	<b>0</b>	<b>264</b>	<b>(0)</b>	<b>(2)</b>	<b>(72)</b>	<b>-</b>	<b>-</b>	<b>1,486</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended March 31, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	348	(22)	-	45	(0)	-	-	-	370
Medication Management Solutions	94	0	-	-	-	-	-	-	94
Diabetes Care	118	-	-	-	-	-	-	-	118
Pharmaceutical Systems	229	-	-	-	-	-	-	-	229
Respiratory Solutions	64	-	-	-	-	(64)	-	-	-
<b>TOTAL</b>	<b>853</b>	<b>(22)</b>	<b>-</b>	<b>45</b>	<b>(0)</b>	<b>(64)</b>	<b>-</b>	<b>-</b>	<b>812</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	165	-	-	-	-	-	-	-	165
Diagnostic Systems	163	-	-	-	-	-	-	-	163
Biosciences	167	-	-	-	-	-	-	-	167
<b>TOTAL</b>	<b>495</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>495</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	21	-	33	(0)	(3)	-	-	50
Peripheral Intervention	-	1	-	109	(1)	-	-	-	110
Urology and Critical Care	-	-	-	62	(0)	-	-	-	62
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	83	(83)	-	-	-	-	-
<i>Urology</i>	-	-	57	(57)	-	-	-	-	-
<i>Oncology</i>	-	-	69	(69)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	33	(33)	-	-	-	-	-
<i>Other</i>	-	-	7	(7)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>22</b>	<b>249</b>	<b>(45)</b>	<b>(1)</b>	<b>(3)</b>	<b>-</b>	<b>-</b>	<b>222</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,349</b>	<b>0</b>	<b>249</b>	<b>-</b>	<b>(1)</b>	<b>(67)</b>	<b>-</b>	<b>-</b>	<b>1,529</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended June 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	378	(24)	-	52	(0)	-	-	-	405
Medication Management Solutions	112	-	-	-	-	-	-	-	112
Diabetes Care	132	-	-	-	-	-	-	-	132
Pharmaceutical Systems	244	-	-	-	-	-	-	-	244
Respiratory Solutions	63	-	-	-	-	(63)	-	-	-
<b>TOTAL</b>	<b>928</b>	<b>(24)</b>	<b>-</b>	<b>52</b>	<b>(0)</b>	<b>(63)</b>	<b>-</b>	<b>-</b>	<b>893</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	186	-	-	-	-	-	-	-	186
Diagnostic Systems	185	-	-	-	-	-	-	-	185
Biosciences	164	-	-	-	-	-	-	-	164
<b>TOTAL</b>	<b>535</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>535</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	23	-	40	(0)	(2)	-	-	60
Peripheral Intervention	-	1	-	124	(1)	-	-	-	124
Urology and Critical Care	-	-	-	82	(0)	-	-	-	82
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	94	(94)	-	-	-	-	-
<i>Urology</i>	-	-	77	(77)	-	-	-	-	-
<i>Oncology</i>	-	-	79	(79)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	40	(40)	-	-	-	-	-
<i>Other</i>	-	-	7	(7)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>24</b>	<b>298</b>	<b>(52)</b>	<b>(1)</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>267</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,463</b>	<b>0</b>	<b>298</b>	<b>0</b>	<b>(2)</b>	<b>(65)</b>	<b>-</b>	<b>-</b>	<b>1,694</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended September 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	372	(24)	-	54	(0)	-	-	-	401
Medication Management Solutions	107	-	-	-	-	-	-	-	107
Diabetes Care	131	-	-	-	-	-	-	-	131
Pharmaceutical Systems	265	-	-	-	-	-	-	-	265
Respiratory Solutions	67	0	-	-	-	(67)	-	-	-
<b>TOTAL</b>	<b>941</b>	<b>(24)</b>	<b>-</b>	<b>54</b>	<b>(0)</b>	<b>(67)</b>	<b>-</b>	<b>-</b>	<b>903</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	177	-	-	-	-	-	-	-	177
Diagnostic Systems	189	-	-	-	-	-	-	-	189
Biosciences	177	-	-	-	-	-	-	-	177
<b>TOTAL</b>	<b>542</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>542</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	23	-	38	(0)	(2)	-	-	58
Peripheral Intervention	-	1	-	123	(1)	-	-	-	123
Urology and Critical Care	-	-	-	82	(0)	-	-	-	82
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	92	(92)	-	-	-	-	-
<i>Urology</i>	-	-	77	(77)	-	-	-	-	-
<i>Oncology</i>	-	-	81	(81)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	38	(38)	-	-	-	-	-
<i>Other</i>	-	-	7	(7)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>24</b>	<b>296</b>	<b>(54)</b>	<b>(1)</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>263</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,483</b>	<b>(0)</b>	<b>296</b>	<b>(0)</b>	<b>(2)</b>	<b>(69)</b>	<b>-</b>	<b>-</b>	<b>1,708</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>12 Months Ended September 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	1,454	(92)	-	198	(1)	-	-	-	1,559
Medication Management Solutions	419	-	-	-	-	-	-	-	419
Diabetes Care	502	-	-	-	-	-	-	-	502
Pharmaceutical Systems	872	-	-	-	-	-	-	-	872
Respiratory Solutions	263	-	-	-	-	(263)	-	-	-
<b>TOTAL</b>	<b>3,510</b>	<b>(92)</b>	<b>-</b>	<b>198</b>	<b>(1)</b>	<b>(263)</b>	<b>-</b>	<b>-</b>	<b>3,351</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	694	-	-	-	-	-	-	-	694
Diagnostic Systems	701	-	-	-	-	-	-	-	701
Biosciences	685	-	-	-	-	-	-	-	685
<b>TOTAL</b>	<b>2,080</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,080</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	87	-	143	(2)	(10)	-	-	218
Peripheral Intervention	-	5	-	466	(3)	-	-	-	468
Urology and Critical Care	-	-	-	300	(1)	-	-	-	299
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	355	(355)	-	-	-	-	-
<i>Urology</i>	-	-	281	(281)	-	-	-	-	-
<i>Oncology</i>	-	-	299	(299)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	143	(143)	-	-	-	-	-
<i>Other</i>	-	-	29	(29)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>92</b>	<b>1,107</b>	<b>(198)</b>	<b>(5)</b>	<b>(10)</b>	<b>-</b>	<b>-</b>	<b>986</b>
<b>TOTAL INTERNATIONAL</b>	<b>5,590</b>	<b>0</b>	<b>1,107</b>	<b>-</b>	<b>(6)</b>	<b>(274)</b>	<b>-</b>	<b>-</b>	<b>6,418</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended December 31, 2016</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	374	(24)	-	57	(0)	-	-	-	406	382	6.2%	8.3%	(8)
Medication Management Solutions	109	-	-	-	-	-	-	-	109	106	2.9%	6.9%	(4)
Diabetes Care	124	-	-	-	-	-	-	-	124	121	1.8%	1.6%	0
Pharmaceutical Systems	165	-	-	-	-	-	-	-	165	133	23.5%	23.3%	0
Respiratory Solutions	(0)	0	-	-	-	0	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>771</b>	<b>(24)</b>	<b>-</b>	<b>57</b>	<b>(0)</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>804</b>	<b>743</b>	<b>8.1%</b>	<b>9.7%</b>	<b>(12)</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	179	-	-	-	-	-	-	-	179	166	7.8%	9.7%	(3)
Diagnostic Systems	179	-	-	-	-	-	-	-	179	164	9.1%	9.1%	0
Biosciences	163	-	-	-	-	-	-	-	163	177	-8.1%	-7.4%	(1)
<b>TOTAL</b>	<b>521</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>521</b>	<b>508</b>	<b>2.7%</b>	<b>3.5%</b>	<b>(4)</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	23	-	42	(1)	(2)	-	-	62	50	23.2%	28.2%	(3)
Peripheral Intervention	-	1	-	127	(1)	-	-	-	127	111	14.6%	15.2%	(1)
Urology and Critical Care	-	-	-	87	(0)	-	-	-	87	74	17.5%	19.1%	(1)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	97	(97)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	82	(82)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	84	(84)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	42	(42)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	7	(7)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>24</b>	<b>312</b>	<b>(57)</b>	<b>(1)</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>276</b>	<b>235</b>	<b>17.4%</b>	<b>19.2%</b>	<b>(4)</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,292</b>	<b>(0)</b>	<b>312</b>	<b>-</b>	<b>(2)</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>1,600</b>	<b>1,486</b>	<b>7.7%</b>	<b>9.1%</b>	<b>(20)</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended March 31, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	370	(23)	-	49	(0)	-	-	-	397	370	7.2%	8.7%	(6)
Medication Management Solutions	103	-	-	-	-	-	-	-	103	94	9.6%	13.6%	(4)
Diabetes Care	119	-	-	-	-	-	-	-	119	118	0.7%	1.7%	(1)
Pharmaceutical Systems	235	-	-	-	-	-	-	-	235	229	2.6%	5.6%	(7)
Respiratory Solutions	(0)	(0)	-	-	-	0	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>828</b>	<b>(23)</b>	<b>-</b>	<b>49</b>	<b>(0)</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>854</b>	<b>812</b>	<b>5.2%</b>	<b>7.4%</b>	<b>(18)</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	177	-	-	-	-	-	-	-	177	165	7.1%	9.1%	(3)
Diagnostic Systems	178	-	-	-	-	-	-	-	178	163	9.2%	10.6%	(2)
Biosciences	160	-	-	-	-	-	-	-	160	167	-4.5%	-2.9%	(3)
<b>TOTAL</b>	<b>514</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>514</b>	<b>495</b>	<b>3.9%</b>	<b>5.6%</b>	<b>(8)</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	21	-	40	(0)	(3)	-	-	58	50	15.8%	20.3%	(2)
Peripheral Intervention	-	1	-	119	(1)	-	-	-	120	110	8.8%	11.0%	(2)
Urology and Critical Care	-	-	-	73	(0)	-	-	-	73	62	18.5%	22.5%	(2)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	92	(92)	-	-	-	-	-	-			
<i>Urology</i>	-	-	69	(69)	-	-	-	-	-	-			
<i>Oncology</i>	-	-	74	(74)	-	-	-	-	-	-			
<i>Surgical Specialties</i>	-	-	40	(40)	-	-	-	-	-	-			
<i>Other</i>	-	-	6	(6)	-	-	-	-	-	-			
<b>TOTAL</b>	<b>-</b>	<b>23</b>	<b>282</b>	<b>(49)</b>	<b>(1)</b>	<b>(3)</b>	<b>-</b>	<b>-</b>	<b>251</b>	<b>222</b>	<b>13.1%</b>	<b>16.3%</b>	<b>(7)</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,342</b>	<b>0</b>	<b>282</b>	<b>0</b>	<b>(1)</b>	<b>(3)</b>	<b>-</b>	<b>-</b>	<b>1,620</b>	<b>1,529</b>	<b>5.9%</b>	<b>8.1%</b>	<b>(33)</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended June 30, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	389	(22)	-	59	(0)	-	-	-	426	405	5.2%	7.8%	(11)
Medication Management Solutions	109	-	-	-	-	-	-	-	109	112	-3.0%	1.0%	(4)
Diabetes Care	131	-	-	-	-	-	-	-	131	132	-0.7%	1.2%	(3)
Pharmaceutical Systems	258	-	-	-	-	-	-	-	258	244	5.6%	7.5%	(5)
Respiratory Solutions	0	0	-	-	-	(0)	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>886</b>	<b>(22)</b>	<b>-</b>	<b>59</b>	<b>(0)</b>	<b>(0)</b>	<b>-</b>	<b>-</b>	<b>923</b>	<b>893</b>	<b>3.4%</b>	<b>5.9%</b>	<b>(22)</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	185	-	-	-	-	-	-	-	185	186	-0.5%	2.0%	(5)
Diagnostic Systems	191	-	-	-	-	-	-	-	191	185	3.0%	5.0%	(4)
Biosciences	171	-	-	-	-	-	-	-	171	164	4.2%	6.4%	(4)
<b>TOTAL</b>	<b>547</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>547</b>	<b>535</b>	<b>2.2%</b>	<b>4.4%</b>	<b>(12)</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	20	-	46	(1)	(2)	-	-	64	60	6.0%	10.7%	(3)
Peripheral Intervention	-	1	-	135	(1)	-	-	-	136	124	9.1%	12.4%	(4)
Urology and Critical Care	-	-	-	80	(0)	-	-	-	80	82	-3.2%	1.5%	(4)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	104	(104)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	76	(76)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	87	(87)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	46	(46)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	7	(7)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>22</b>	<b>320</b>	<b>(59)</b>	<b>(2)</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>279</b>	<b>267</b>	<b>4.6%</b>	<b>8.7%</b>	<b>(11)</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,433</b>	<b>0</b>	<b>320</b>	<b>0</b>	<b>(2)</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>1,749</b>	<b>1,694</b>	<b>3.2%</b>	<b>5.9%</b>	<b>(45)</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended September 30, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	396	(26)	-	64	(0)	-	-	-	434	401	8.2%	7.9%	1
Medication Management Solutions	131	-	-	-	-	-	-	-	131	107	22.9%	21.5%	1
Diabetes Care	136	(0)	-	-	-	-	-	-	136	131	4.4%	4.1%	0
Pharmaceutical Systems	271	-	-	-	-	-	-	-	271	265	2.3%	0.4%	5
Respiratory Solutions	0	0	-	-	-	(0)	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>934</b>	<b>(26)</b>	<b>-</b>	<b>64</b>	<b>(0)</b>	<b>(0)</b>	<b>-</b>	<b>-</b>	<b>972</b>	<b>903</b>	<b>7.6%</b>	<b>6.7%</b>	<b>8</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	189	-	-	-	-	-	-	-	189	177	6.8%	6.8%	(0)
Diagnostic Systems	208	-	-	-	-	-	-	-	208	189	10.5%	10.7%	(0)
Biosciences	191	-	-	-	-	-	-	-	191	177	7.7%	7.3%	1
<b>TOTAL</b>	<b>588</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>588</b>	<b>542</b>	<b>8.4%</b>	<b>8.3%</b>	<b>0</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	24	-	41	(0)	(3)	-	-	63	58	8.5%	9.1%	(0)
Peripheral Intervention	-	2	-	137	(1)	-	-	-	138	123	12.1%	11.8%	0
Urology and Critical Care	-	-	-	81	(0)	-	-	-	81	82	-0.8%	1.9%	(2)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	105	(105)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	77	(77)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	93	(93)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	41	(41)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	7	(7)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>26</b>	<b>324</b>	<b>(64)</b>	<b>(1)</b>	<b>(3)</b>	<b>-</b>	<b>-</b>	<b>282</b>	<b>263</b>	<b>7.3%</b>	<b>8.2%</b>	<b>(2)</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,522</b>	<b>(0)</b>	<b>324</b>	<b>0</b>	<b>(1)</b>	<b>(3)</b>	<b>-</b>	<b>-</b>	<b>1,842</b>	<b>1,708</b>	<b>7.8%</b>	<b>7.5%</b>	<b>6</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>12 Months Ended September 30, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	1,529	(95)	-	229	(1)	-	-	-	1,663	1,559	6.7%	8.1%	(23)
Medication Management Solutions	452	-	-	-	-	-	-	-	452	419	7.9%	10.6%	(11)
Diabetes Care	510	-	-	-	-	-	-	-	510	502	1.6%	2.2%	(3)
Pharmaceutical Systems	929	-	-	-	-	-	-	-	929	872	6.6%	7.3%	(6)
Respiratory Solutions	0	0	-	-	-	(0)	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>3,419</b>	<b>(95)</b>	<b>-</b>	<b>229</b>	<b>(1)</b>	<b>(0)</b>	<b>-</b>	<b>-</b>	<b>3,553</b>	<b>3,351</b>	<b>6.0%</b>	<b>7.3%</b>	<b>(44)</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	730	-	-	-	-	-	-	-	730	694	5.2%	6.8%	(11)
Diagnostic Systems	756	-	-	-	-	-	-	-	756	701	7.9%	8.8%	(6)
Biosciences	684	-	-	-	-	-	-	-	684	685	-0.2%	0.8%	(7)
<b>TOTAL</b>	<b>2,170</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,170</b>	<b>2,080</b>	<b>4.3%</b>	<b>5.5%</b>	<b>(24)</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	89	-	169	(2)	(10)	-	-	247	218	12.9%	16.5%	(8)
Peripheral Intervention	-	6	-	518	(3)	-	-	-	521	468	11.1%	12.6%	(7)
Urology and Critical Care	-	-	-	321	(0)	-	-	-	320	299	7.0%	10.3%	(10)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	398	(398)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	305	(305)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	338	(338)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	169	(169)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	27	(27)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>95</b>	<b>1,237</b>	<b>(229)</b>	<b>(5)</b>	<b>(10)</b>	<b>-</b>	<b>-</b>	<b>1,088</b>	<b>986</b>	<b>10.3%</b>	<b>12.8%</b>	<b>(24)</b>
<b>TOTAL INTERNATIONAL</b>	<b>5,589</b>	<b>(0)</b>	<b>1,237</b>	<b>0</b>	<b>(6)</b>	<b>(10)</b>	<b>-</b>	<b>-</b>	<b>6,811</b>	<b>6,418</b>	<b>6.1%</b>	<b>7.6%</b>	<b>(92)</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - INTERNATIONAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended December 31, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	398	(26)	-	68	(0)	-	-	-	440	406	8.4%	5.0%	14
Medication Management Solutions	116	-	-	-	-	-	-	-	116	109	6.5%	0.6%	6
Diabetes Care	132	-	-	-	-	-	-	-	132	124	6.4%	3.2%	4
Pharmaceutical Systems	192	-	-	-	-	-	-	-	192	165	16.4%	10.4%	10
Respiratory Solutions	(0)	(0)	-	-	-	0	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>837</b>	<b>(26)</b>	<b>-</b>	<b>68</b>	<b>(0)</b>	<b>0</b>	<b>-</b>	<b>-</b>	<b>880</b>	<b>804</b>	<b>9.5%</b>	<b>5.2%</b>	<b>34</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	191	-	-	-	-	-	-	-	191	179	6.6%	3.4%	6
Diagnostic Systems	214	-	-	-	-	-	-	-	214	179	19.4%	16.2%	6
Biosciences	181	-	-	-	-	-	-	-	181	163	11.0%	7.8%	5
<b>TOTAL</b>	<b>586</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>586</b>	<b>521</b>	<b>12.4%</b>	<b>9.2%</b>	<b>17</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	25	-	49	(0)	(2)	-	-	71	62	14.7%	10.2%	3
Peripheral Intervention	-	1	-	147	(1)	-	-	-	147	127	15.9%	12.0%	5
Urology and Critical Care	-	-	-	90	(0)	-	-	-	90	87	4.4%	2.3%	2
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	114	(114)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	86	(86)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	98	(98)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	49	(49)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	8	(8)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>26</b>	<b>355</b>	<b>(68)</b>	<b>(1)</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>309</b>	<b>276</b>	<b>12.0%</b>	<b>8.6%</b>	<b>9</b>
<b>TOTAL INTERNATIONAL</b>	<b>1,423</b>	<b>(0)</b>	<b>355</b>	<b>0</b>	<b>(2)</b>	<b>(2)</b>	<b>-</b>	<b>-</b>	<b>1,774</b>	<b>1,600</b>	<b>10.9%</b>	<b>7.1%</b>	<b>60</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended December 31, 2015</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	848	(170)	-	182	-	(7)	-	(3)	850
Medication Management Solutions	545	-	-	-	-	-	-	-	545
Diabetes Care	256	-	-	-	-	-	-	-	256
Pharmaceutical Systems	197	-	-	-	-	-	-	-	197
Respiratory Solutions	208	-	-	-	-	(208)	-	-	-
<b>TOTAL</b>	<b>2,054</b>	<b>(170)</b>	<b>-</b>	<b>182</b>	<b>-</b>	<b>(216)</b>	<b>-</b>	<b>(3)</b>	<b>1,847</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	344	-	-	-	-	-	-	-	344
Diagnostic Systems	313	-	-	-	-	-	-	-	313
Biosciences	276	-	-	-	-	-	-	-	276
<b>TOTAL</b>	<b>933</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>933</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	165	-	157	-	(12)	-	(0)	311
Peripheral Intervention	-	5	-	309	-	-	(38)	-	276
Urology and Critical Care	-	-	-	222	-	-	-	-	222
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	239	(239)	-	-	-	-	-
<i>Urology</i>	-	-	218	(218)	-	-	-	-	-
<i>Oncology</i>	-	-	238	(238)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	153	(153)	-	-	-	-	-
<i>Other</i>	-	-	23	(23)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>170</b>	<b>871</b>	<b>(182)</b>	<b>-</b>	<b>(12)</b>	<b>(38)</b>	<b>(0)</b>	<b>809</b>
<b>TOTAL WORLDWIDE</b>	<b>2,986</b>	<b>-</b>	<b>871</b>	<b>(0)</b>	<b>-</b>	<b>(227)</b>	<b>(38)</b>	<b>(3)</b>	<b>3,589</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended March 31, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	831	(177)	-	183	-	(6)	-	(3)	828
Medication Management Solutions	533	-	-	-	-	-	-	-	533
Diabetes Care	243	-	-	-	-	-	-	-	243
Pharmaceutical Systems	311	-	-	-	-	-	-	-	311
Respiratory Solutions	213	-	-	-	-	(213)	-	-	-
<b>TOTAL</b>	<b>2,131</b>	<b>(177)</b>	<b>-</b>	<b>183</b>	<b>-</b>	<b>(219)</b>	<b>-</b>	<b>(3)</b>	<b>1,916</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	340	-	-	-	-	-	-	-	340
Diagnostic Systems	319	-	-	-	-	-	-	-	319
Biosciences	277	-	-	-	-	-	-	-	277
<b>TOTAL</b>	<b>936</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>936</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	172	-	156	-	(12)	-	(0)	315
Peripheral Intervention	-	5	-	313	-	-	(38)	-	279
Urology and Critical Care	-	-	-	222	-	-	-	-	222
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	240	(240)	-	-	-	-	-
<i>Urology</i>	-	-	217	(217)	-	-	-	-	-
<i>Oncology</i>	-	-	242	(242)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	151	(151)	-	-	-	-	-
<i>Other</i>	-	-	24	(24)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>177</b>	<b>874</b>	<b>(183)</b>	<b>-</b>	<b>(12)</b>	<b>(38)</b>	<b>(0)</b>	<b>816</b>
<b>TOTAL WORLDWIDE</b>	<b>3,067</b>	<b>(0)</b>	<b>874</b>	<b>-</b>	<b>-</b>	<b>(231)</b>	<b>(38)</b>	<b>(3)</b>	<b>3,668</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended June 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	851	(167)	-	192	-	(3)	-	(4)	870
Medication Management Solutions	585	0	-	-	-	-	-	-	585
Diabetes Care	258	-	-	-	-	-	-	-	258
Pharmaceutical Systems	342	-	-	-	-	-	-	-	342
Respiratory Solutions	199	-	-	-	-	(199)	-	-	-
<b>TOTAL</b>	<b>2,235</b>	<b>(167)</b>	<b>-</b>	<b>192</b>	<b>-</b>	<b>(202)</b>	<b>-</b>	<b>(4)</b>	<b>2,055</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	366	-	-	-	-	-	-	-	366
Diagnostic Systems	327	-	-	-	-	-	-	-	327
Biosciences	270	-	-	-	-	-	-	-	270
<b>TOTAL</b>	<b>963</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>963</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	162	-	164	-	(12)	-	(0)	314
Peripheral Intervention	-	5	-	331	-	-	(39)	-	297
Urology and Critical Care	-	-	-	244	-	-	-	-	244
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	255	(255)	-	-	-	-	-
<i>Urology</i>	-	-	240	(240)	-	-	-	-	-
<i>Oncology</i>	-	-	252	(252)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	160	(160)	-	-	-	-	-
<i>Other</i>	-	-	24	(24)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>167</b>	<b>931</b>	<b>(192)</b>	<b>-</b>	<b>(12)</b>	<b>(39)</b>	<b>(0)</b>	<b>855</b>
<b>TOTAL WORLDWIDE</b>	<b>3,198</b>	<b>(0)</b>	<b>931</b>	<b>-</b>	<b>-</b>	<b>(214)</b>	<b>(39)</b>	<b>(4)</b>	<b>3,873</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>3 Months Ended September 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	882	(178)	-	196	-	(3)	-	(4)	893
Medication Management Solutions	534	(0)	-	-	-	-	-	-	534
Diabetes Care	266	-	-	-	-	-	-	-	266
Pharmaceutical Systems	350	-	-	-	-	-	-	-	350
Respiratory Solutions	202	-	-	-	-	(202)	-	-	-
<b>TOTAL</b>	<b>2,235</b>	<b>(178)</b>	<b>-</b>	<b>196</b>	<b>-</b>	<b>(205)</b>	<b>-</b>	<b>(4)</b>	<b>2,043</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	359	-	-	-	-	-	-	-	359
Diagnostic Systems	342	-	-	-	-	-	-	-	342
Biosciences	296	-	-	-	-	-	-	-	296
<b>TOTAL</b>	<b>996</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>996</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	173	-	164	-	(12)	-	(0)	325
Peripheral Intervention	-	5	-	336	-	-	(43)	-	298
Urology and Critical Care	-	-	-	247	-	-	-	-	247
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	258	(258)	-	-	-	-	-
<i>Urology</i>	-	-	242	(242)	-	-	-	-	-
<i>Oncology</i>	-	-	258	(258)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	159	(159)	-	-	-	-	-
<i>Other</i>	-	-	24	(24)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>178</b>	<b>942</b>	<b>(196)</b>	<b>-</b>	<b>(12)</b>	<b>(43)</b>	<b>(0)</b>	<b>870</b>
<b>TOTAL WORLDWIDE</b>	<b>3,231</b>	<b>0</b>	<b>942</b>	<b>-</b>	<b>-</b>	<b>(217)</b>	<b>(43)</b>	<b>(4)</b>	<b>3,910</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted
<b>12 Months Ended September 30, 2016</b>									
<b>BD MEDICAL</b>									
Medication Delivery Solutions (previously Medication and Procedural Solutions)	3,413	(692)	-	754	-	(19)	-	(14)	3,442
Medication Management Solutions	2,197	-	-	-	-	-	-	-	2,197
Diabetes Care	1,023	-	-	-	-	-	-	-	1,023
Pharmaceutical Systems	1,199	-	-	-	-	-	-	-	1,199
Respiratory Solutions	822	(0)	-	-	-	(822)	-	-	-
<b>TOTAL</b>	<b>8,654</b>	<b>(692)</b>	<b>-</b>	<b>754</b>	<b>-</b>	<b>(842)</b>	<b>-</b>	<b>(14)</b>	<b>7,861</b>
<b>BD LIFE SCIENCES</b>									
Preanalytical Systems	1,409	-	-	-	-	-	-	-	1,409
Diagnostic Systems	1,301	-	-	-	-	-	-	-	1,301
Biosciences	1,119	-	-	-	-	-	-	-	1,119
<b>TOTAL</b>	<b>3,829</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,829</b>
<b>BD INTERVENTIONAL</b>									
Surgery	-	672	-	641	-	(47)	-	(0)	1,266
Peripheral Intervention	-	20	-	1,288	-	-	(158)	-	1,150
Urology and Critical Care	-	-	-	935	-	-	-	-	935
<i>Legacy Bard Product Groups</i>									
<i>Vascular</i>	-	-	992	(992)	-	-	-	-	-
<i>Urology</i>	-	-	917	(917)	-	-	-	-	-
<i>Oncology</i>	-	-	991	(991)	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	623	(623)	-	-	-	-	-
<i>Other</i>	-	-	95	(95)	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>692</b>	<b>3,618</b>	<b>(754)</b>	<b>-</b>	<b>(47)</b>	<b>(158)</b>	<b>(0)</b>	<b>3,350</b>
<b>TOTAL WORLDWIDE</b>	<b>12,483</b>	<b>0</b>	<b>3,618</b>	<b>-</b>	<b>-</b>	<b>(889)</b>	<b>(158)</b>	<b>(14)</b>	<b>15,040</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended December 31, 2016</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	868.7	(173)	-	195	-	-	-	(4)	887	850	4.3%	5.2%	(8)
Medication Management Solutions	601	0	-	-	-	-	-	-	601	545	10.2%	11.0%	(4)
Diabetes Care	267	-	-	-	-	-	-	-	267	256	4.6%	4.5%	0
Pharmaceutical Systems	227	-	-	-	-	-	-	-	227	197	15.6%	15.5%	0
Respiratory Solutions	(0)	0	-	-	-	0	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>1,964</b>	<b>(173)</b>	<b>-</b>	<b>195</b>	<b>-</b>	<b>0</b>	<b>-</b>	<b>(4)</b>	<b>1,982</b>	<b>1,847</b>	<b>7.3%</b>	<b>7.9%</b>	<b>(12)</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	355	-	-	-	-	-	-	-	355	344	3.3%	4.2%	(3)
Diagnostic Systems	334	-	-	-	-	-	-	-	334	313	6.4%	6.4%	0
Biosciences	270	-	-	-	-	-	-	-	270	276	-2.2%	-1.7%	(1)
<b>TOTAL</b>	<b>958</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>958</b>	<b>933</b>	<b>2.7%</b>	<b>3.2%</b>	<b>(4)</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	169	-	172	-	(12)	-	(0)	328	311	5.7%	6.5%	(3)
Peripheral Intervention	-	5	-	339	-	-	(41)	-	302	276	9.5%	9.7%	(1)
Urology and Critical Care	-	-	-	261	-	-	-	-	261	222	17.3%	17.8%	(1)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	262	(262)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	253	(253)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	259	(259)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	167	(167)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	26	(26)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>173</b>	<b>967</b>	<b>(195)</b>	<b>-</b>	<b>(12)</b>	<b>(41)</b>	<b>(0)</b>	<b>892</b>	<b>809</b>	<b>10.2%</b>	<b>10.7%</b>	<b>(4)</b>
<b>TOTAL WORLDWIDE</b>	<b>2,922</b>	<b>0</b>	<b>967</b>	<b>-</b>	<b>-</b>	<b>(12)</b>	<b>(41)</b>	<b>(4)</b>	<b>3,832</b>	<b>3,589</b>	<b>6.8%</b>	<b>7.3%</b>	<b>(20)</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended March 31, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	865	(173)	-	195	-	-	-	(4)	885	828	6.8%	7.5%	(6)
Medication Management Solutions	567	-	-	-	-	-	-	-	567	533	6.3%	7.0%	(4)
Diabetes Care	243	0	-	-	-	-	-	-	243	243	0.0%	0.5%	(1)
Pharmaceutical Systems	312	-	-	-	-	-	-	-	312	311	0.4%	2.6%	(7)
Respiratory Solutions	(0)	(0)	-	-	-	0	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>1,987</b>	<b>(173)</b>	<b>-</b>	<b>195</b>	<b>-</b>	<b>0</b>	<b>-</b>	<b>(4)</b>	<b>2,006</b>	<b>1,916</b>	<b>4.7%</b>	<b>5.7%</b>	<b>(18)</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	363	-	-	-	-	-	-	-	363	340	6.6%	7.5%	(3)
Diagnostic Systems	350	-	-	-	-	-	-	-	350	319	9.8%	10.5%	(2)
Biosciences	269	-	-	-	-	-	-	-	269	277	-2.8%	-1.8%	(3)
<b>TOTAL</b>	<b>982</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>982</b>	<b>936</b>	<b>4.9%</b>	<b>5.8%</b>	<b>(8)</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	168	-	170	-	(12)	-	(0)	326	315	3.2%	3.9%	(2)
Peripheral Intervention	-	5	-	331	-	-	(42)	-	294	279	5.3%	6.2%	(2)
Urology and Critical Care	-	-	-	242	-	-	-	-	242	222	9.1%	10.2%	(2)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	257	(257)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	238	(238)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	255	(255)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	165	(165)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	24	(24)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>173</b>	<b>939</b>	<b>(195)</b>	<b>-</b>	<b>(12)</b>	<b>(42)</b>	<b>(0)</b>	<b>862</b>	<b>816</b>	<b>5.5%</b>	<b>6.4%</b>	<b>(7)</b>
<b>TOTAL WORLDWIDE</b>	<b>2,969</b>	<b>0</b>	<b>939</b>	<b>-</b>	<b>-</b>	<b>(12)</b>	<b>(42)</b>	<b>(4)</b>	<b>3,850</b>	<b>3,668</b>	<b>5.0%</b>	<b>5.9%</b>	<b>(33)</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended June 30, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	870	(167)	-	203	-	-	-	(3)	902	870	3.7%	4.9%	(11)
Medication Management Solutions	556	0	-	-	-	-	-	-	556	585	-5.0%	-4.2%	(4)
Diabetes Care	263	-	-	-	-	-	-	-	263	258	1.7%	2.7%	(3)
Pharmaceutical Systems	350	-	-	-	-	-	-	-	350	342	2.5%	3.9%	(5)
Respiratory Solutions	0	0	-	-	-	(0)	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>2,038</b>	<b>(167)</b>	<b>-</b>	<b>203</b>	<b>-</b>	<b>(0)</b>	<b>-</b>	<b>(3)</b>	<b>2,070</b>	<b>2,055</b>	<b>0.8%</b>	<b>1.8%</b>	<b>(22)</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	376	-	-	-	-	-	-	-	376	366	2.6%	3.9%	(5)
Diagnostic Systems	335	-	-	-	-	-	-	-	335	327	2.6%	3.8%	(4)
Biosciences	286	-	-	-	-	-	-	-	286	270	5.8%	7.1%	(4)
<b>TOTAL</b>	<b>997</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>997</b>	<b>963</b>	<b>3.5%</b>	<b>4.8%</b>	<b>(12)</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	163	-	175	-	(11)	-	(0)	326	314	3.7%	4.6%	(3)
Peripheral Intervention	-	5	-	356	-	-	(44)	-	317	297	6.9%	8.3%	(4)
Urology and Critical Care	-	-	-	246	-	-	-	-	246	244	1.1%	2.7%	(4)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	278	(278)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	241	(241)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	266	(266)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	170	(170)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	25	(25)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>167</b>	<b>980</b>	<b>(203)</b>	<b>-</b>	<b>(11)</b>	<b>(44)</b>	<b>(0)</b>	<b>889</b>	<b>855</b>	<b>4.0%</b>	<b>5.3%</b>	<b>(11)</b>
<b>TOTAL WORLDWIDE</b>	<b>3,035</b>	<b>0</b>	<b>980</b>	<b>-</b>	<b>-</b>	<b>(11)</b>	<b>(44)</b>	<b>(3)</b>	<b>3,957</b>	<b>3,873</b>	<b>2.2%</b>	<b>3.3%</b>	<b>(45)</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended September 30, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	894	(172)	-	207	-	-	-	(3)	925	893	3.5%	3.4%	1
Medication Management Solutions	571	(0)	-	-	-	-	-	-	571	534	6.9%	6.7%	1
Diabetes Care	283	(0)	-	-	-	-	-	-	283	266	6.6%	6.4%	0
Pharmaceutical Systems	367	-	-	-	-	-	-	-	367	350	4.9%	3.4%	5
Respiratory Solutions	0	0	-	-	-	(0)	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>2,115</b>	<b>(172)</b>	<b>-</b>	<b>207</b>	<b>-</b>	<b>(0)</b>	<b>-</b>	<b>(3)</b>	<b>2,146</b>	<b>2,043</b>	<b>5.0%</b>	<b>4.6%</b>	<b>8</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	378	-	-	-	-	-	-	-	378	359	5.3%	5.3%	(0)
Diagnostic Systems	359	-	-	-	-	-	-	-	359	342	5.1%	5.2%	(0)
Biosciences	314	-	-	-	-	-	-	-	314	296	6.1%	5.8%	1
<b>TOTAL</b>	<b>1,051</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,051</b>	<b>996</b>	<b>5.5%</b>	<b>5.4%</b>	<b>0</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	167	-	163	-	(13)	-	(0)	318	325	-2.1%	-2.0%	(0)
Peripheral Intervention	-	5	-	367	-	-	(47)	-	325	298	9.2%	9.1%	0
Urology and Critical Care	-	-	-	253	-	-	-	-	253	247	2.3%	3.2%	(2)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	289	(289)	-	-	-	-	-	-			
<i>Urology</i>	-	-	248	(248)	-	-	-	-	-	-			
<i>Oncology</i>	-	-	271	(271)	-	-	-	-	-	-			
<i>Surgical Specialties</i>	-	-	158	(158)	-	-	-	-	-	-			
<i>Other</i>	-	-	24	(24)	-	-	-	-	-	-			
<b>TOTAL</b>	<b>-</b>	<b>172</b>	<b>990</b>	<b>(207)</b>	<b>-</b>	<b>(13)</b>	<b>(47)</b>	<b>(0)</b>	<b>896</b>	<b>870</b>	<b>3.0%</b>	<b>3.3%</b>	<b>(2)</b>
<b>TOTAL WORLDWIDE</b>	<b>3,166</b>	<b>(0)</b>	<b>990</b>	<b>-</b>	<b>-</b>	<b>(13)</b>	<b>(47)</b>	<b>(4)</b>	<b>4,093</b>	<b>3,910</b>	<b>4.7%</b>	<b>4.5%</b>	<b>6</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>12 Months Ended September 30, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	3,497	(685)	-	800	-	-	-	(14)	3,598	3,442	4.5%	5.2%	(23)
Medication Management Solutions	2,295	-	-	-	-	-	-	-	2,295	2,197	4.4%	4.9%	(11)
Diabetes Care	1,056	-	-	-	-	-	-	-	1,056	1,023	3.3%	3.6%	(3)
Pharmaceutical Systems	1,256	-	-	-	-	-	-	-	1,256	1,199	4.8%	5.3%	(6)
Respiratory Solutions	0	0	-	-	-	(0)	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>8,105</b>	<b>(685)</b>	<b>-</b>	<b>800</b>	<b>-</b>	<b>(0)</b>	<b>-</b>	<b>(14)</b>	<b>8,205</b>	<b>7,861</b>	<b>4.4%</b>	<b>4.9%</b>	<b>(44)</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	1,471	-	-	-	-	-	-	-	1,471	1,409	4.4%	5.2%	(11)
Diagnostic Systems	1,378	-	-	-	-	-	-	-	1,378	1,301	5.9%	6.4%	(6)
Biosciences	1,139	-	-	-	-	-	-	-	1,139	1,119	1.8%	2.4%	(7)
<b>TOTAL</b>	<b>3,988</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,988</b>	<b>3,829</b>	<b>4.2%</b>	<b>4.8%</b>	<b>(24)</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	666	-	680	-	(48)	-	(0)	1,298	1,266	2.6%	3.2%	(8)
Peripheral Intervention	-	19	-	1,393	-	-	(173)	-	1,239	1,150	7.7%	8.3%	(7)
Urology and Critical Care	-	-	-	1,002	-	-	-	-	1,002	935	7.2%	8.2%	(10)
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	1,085	(1,085)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	980	(980)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	1,052	(1,052)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	660	(660)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	98	(98)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>685</b>	<b>3,875</b>	<b>(800)</b>	<b>-</b>	<b>(48)</b>	<b>(173)</b>	<b>(0)</b>	<b>3,539</b>	<b>3,350</b>	<b>5.6%</b>	<b>6.4%</b>	<b>(24)</b>
<b>TOTAL WORLDWIDE</b>	<b>12,093</b>	<b>0</b>	<b>3,875</b>	<b>-</b>	<b>-</b>	<b>(48)</b>	<b>(173)</b>	<b>(14)</b>	<b>15,732</b>	<b>15,040</b>	<b>4.6%</b>	<b>5.2%</b>	<b>(92)</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - TOTAL  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended December 31, 2017</b>													
<b>BD MEDICAL</b>													
Medication Delivery Solutions (previously Medication and Procedural Solutions)	925	(183)	-	213	-	-	-	(3)	952	887	7.4%	5.8%	14
Medication Management Solutions	587	-	-	-	-	-	-	-	587	601	-2.3%	-3.4%	6
Diabetes Care	277	-	-	-	-	-	-	-	277	267	3.7%	2.2%	4
Pharmaceutical Systems	245	-	-	-	-	-	-	-	245	227	8.0%	3.7%	10
Respiratory Solutions	0	0	-	-	-	(0)	-	-	-	-	NM	NM	-
<b>TOTAL</b>	<b>2,035</b>	<b>(183)</b>	<b>-</b>	<b>213</b>	<b>-</b>	<b>(0)</b>	<b>-</b>	<b>(3)</b>	<b>2,062</b>	<b>1,982</b>	<b>4.0%</b>	<b>2.3%</b>	<b>34</b>
<b>BD LIFE SCIENCES</b>													
Preanalytical Systems	375	-	-	-	-	-	-	-	375	355	5.6%	4.0%	6
Diagnostic Systems	381	-	-	-	-	-	-	-	381	334	14.1%	12.5%	6
Biosciences	289	-	-	-	-	-	-	-	289	270	7.3%	5.3%	5
<b>TOTAL</b>	<b>1,045</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,045</b>	<b>958</b>	<b>9.1%</b>	<b>7.3%</b>	<b>17</b>
<b>BD INTERVENTIONAL</b>													
Surgery	-	177	-	153	-	(12)	-	(0)	318	328	-3.1%	-4.0%	3
Peripheral Intervention	-	6	-	380	-	-	(46)	-	340	302	12.4%	10.7%	5
Urology and Critical Care	-	-	-	267	-	-	-	-	267	261	2.5%	1.8%	2
<i>Legacy Bard Product Groups</i>													
<i>Vascular</i>	-	-	299	(299)	-	-	-	-	-	-	-	-	-
<i>Urology</i>	-	-	262	(262)	-	-	-	-	-	-	-	-	-
<i>Oncology</i>	-	-	278	(278)	-	-	-	-	-	-	-	-	-
<i>Surgical Specialties</i>	-	-	149	(149)	-	-	-	-	-	-	-	-	-
<i>Other</i>	-	-	27	(27)	-	-	-	-	-	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>183</b>	<b>1,013</b>	<b>(213)</b>	<b>-</b>	<b>(12)</b>	<b>(46)</b>	<b>(0)</b>	<b>925</b>	<b>892</b>	<b>3.8%</b>	<b>2.7%</b>	<b>9</b>
<b>TOTAL WORLDWIDE</b>	<b>3,080</b>	<b>(0)</b>	<b>1,013</b>	<b>0</b>	<b>-</b>	<b>(12)</b>	<b>(46)</b>	<b>(3)</b>	<b>4,032</b>	<b>3,832</b>	<b>5.2%</b>	<b>3.6%</b>	<b>60</b>

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>G</b>	<b>H</b>	<b>I=A+B+C+D +E+F+G+H</b>
	<b>BDX as Reported</b>	BD Realign BUs <i>FN#1</i>	Bard as Reported <i>FN#2</i>	Bard Realign BUs <i>FN#3</i>	Bard Align Region Reporting <i>FN#4</i>	Divestiture Adjust <i>FN#5</i>	Gore Royalty Classification Adjust <i>FN#6</i>	Interco Adjust <i>FN#7</i>	<b>Total NewCo as Adjusted</b>
<b><u>3 Months Ended December 31, 2015</u></b>									
EMERGING MARKETS	465	0	87	-	(6)	(31)	-	-	516
DEVELOPED MARKETS	2,521	0	784	(0)	6	(197)	(38)	(3)	3,074
CHINA	163	0	50	-	-	(6)	-	-	206

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>G</b>	<b>H</b>	<b>I=A+B+C+D +E+F+G+H</b>
	<b>BDX as Reported</b>	BD Realign BUs <i>FN#1</i>	Bard as Reported <i>FN#2</i>	Bard Realign BUs <i>FN#3</i>	Bard Align Region Reporting <i>FN#4</i>	Divestiture Adjust <i>FN#5</i>	Gore Royalty Classification Adjust <i>FN#6</i>	Interco Adjust <i>FN#7</i>	<b>Total NewCo as Adjusted</b>
<b><u>3 Months Ended March 31, 2016</u></b>									
EMERGING MARKETS	443	0	84	-	(8)	(23)	-	-	495
DEVELOPED MARKETS	2,625	-	790	-	8	(208)	(38)	(3)	3,173
CHINA	163	(0)	50	-	-	(6)	-	-	207

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL INFORMATION  
 RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
 (Unaudited; Amounts in millions)

	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>G</b>	<b>H</b>	<b>I=A+B+C+D +E+F+G+H</b>
	<b>BDX as Reported</b>	BD Realign BUs <i>FN#1</i>	Bard as Reported <i>FN#2</i>	Bard Realign BUs <i>FN#3</i>	Bard Align Region Reporting <i>FN#4</i>	Divestiture Adjust <i>FN#5</i>	Gore Royalty Classification Adjust <i>FN#6</i>	Interco Adjust <i>FN#7</i>	<b>Total NewCo as Adjusted</b>
<b><u>3 Months Ended June 30, 2016</u></b>									
EMERGING MARKETS	485	(0)	96	(0)	(8)	(24)	-	-	549
DEVELOPED MARKETS	2,713	(0)	836	-	8	(189)	(39)	(4)	3,324
CHINA	170	0	57	-	-	(5)	-	-	222

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>G</b>	<b>H</b>	<b>I=A+B+C+D +E+F+G+H</b>
	<b>BDX as Reported</b>	BD Realign BUs <i>FN#1</i>	Bard as Reported <i>FN#2</i>	Bard Realign BUs <i>FN#3</i>	Bard Align Region Reporting <i>FN#4</i>	Divestiture Adjust <i>FN#5</i>	Gore Royalty Classification Adjust <i>FN#6</i>	Interco Adjust <i>FN#7</i>	<b>Total NewCo as Adjusted</b>
<b><u>3 Months Ended September 30, 2016</u></b>									
EMERGING MARKETS	511	(0)	97	-	(7)	(29)	-	-	572
DEVELOPED MARKETS	2,720	0	845	-	7	(188)	(43)	(4)	3,338
CHINA	167	(0)	58	-	-	(6)	-	-	219

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>G</b>	<b>H</b>	<b>I=A+B+C+D +E+F+G+H</b>
	<b>BDX as Reported</b>	BD Realign BUs <i>FN#1</i>	Bard as Reported <i>FN#2</i>	Bard Realign BUs <i>FN#3</i>	Bard Align Region Reporting <i>FN#4</i>	Divestiture Adjust <i>FN#5</i>	Gore Royalty Classification Adjust <i>FN#6</i>	Interco Adjust <i>FN#7</i>	<b>Total NewCo as Adjusted</b>
<b>12 Months Ended September 30, 2016</b>									
EMERGING MARKETS	1,904	(0)	363	-	(29)	(107)	-	-	2,132
DEVELOPED MARKETS	10,579	0	3,254	-	29	(782)	(158)	(14)	12,908
CHINA	663	0	215	-	-	(23)	-	-	855

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>G</b>	<b>H</b>	<b>I=A+B+C+D +E+F+G+H</b>	<b>J</b>	<b>K=(I-J)/J</b>	<b>L=(I-J- M)/J</b>	<b>M</b>
	<b>BDX as Reported</b>	BD Realign BUs <i>FN#1</i>	Bard as Reported <i>FN#2</i>	Bard Realign BUs <i>FN#3</i>	Bard Align Region Reporting <i>FN#4</i>	Divestiture Adjust <i>FN#5</i>	Gore Royalty Classification Adjust <i>FN#6</i>	Interco Adjust <i>FN#7</i>	<b>Total NewCo as Adjusted</b>	<b>PY Comparable Period</b>	<b>Reported % Change</b>	<b>FXN % Change</b>	<b>FX Impact</b>
<b>3 Months Ended December 31, 2016</b>													
EMERGING MARKETS	456	0	102	-	(7)	(1)	-	-	551	516	6.9%	10.2%	(17)
DEVELOPED MARKETS	2,466	(0)	865	-	7	(12)	(41)	(4)	3,281	3,074	6.7%	6.9%	(3)
CHINA	163	0	57	-	-	(0)	-	-	220	206	6.4%	12.6%	(13)

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended March 31, 2017</b>													
EMERGING MARKETS	452	0	95	0	(8)	(0)	-	-	539	495	8.8%	10.1%	(7)
DEVELOPED MARKETS	2,517	0	844	-	8	(12)	(42)	(4)	3,311	3,173	4.4%	5.2%	(26)
CHINA	168	0	56	-	-	(0)	-	-	223	207	7.7%	13.1%	(11)

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>G</b>	<b>H</b>	<b>I=A+B+C+D +E+F+G+H</b>	<b>J</b>	<b>K=(I-J)/J</b>	<b>L=(I-J- M)/J</b>	<b>M</b>
	<b>BDX as Reported</b>	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	<b>Total NewCo as Adjusted</b>	<b>PY Comparable Period</b>	<b>Reported % Change</b>	<b>FXN % Change</b>	<b>FX Impact</b>
<b>3 Months Ended June 30, 2017</b>													
EMERGING MARKETS	503	0	116	(0)	(9)	(0)	-	-	610	549	11.1%	13.1%	(11)
DEVELOPED MARKETS	2,532	-	863	0	9	(11)	(44)	(3)	3,347	3,324	0.7%	1.7%	(34)
CHINA	176	0	69	-	-	(0)	-	-	245	222	10.2%	15.7%	(12)

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended September 30, 2017</b>													
EMERGING MARKETS	541	0	120	-	(9)	(0)	-	-	652	572	14.0%	14.2%	(1)
DEVELOPED MARKETS	2,625	0	870	-	9	(12)	(47)	(4)	3,441	3,338	3.1%	2.9%	7
CHINA	180	0	72	-	-	(0)	-	-	252	219	15.2%	16.3%	(2)

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>F</b>	<b>G</b>	<b>H</b>	<b>I=A+B+C+D +E+F+G+H</b>	<b>J</b>	<b>K=(I-J)/J</b>	<b>L=(I-J- M)/J</b>	<b>M</b>
	<b>BDX as Reported</b>	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	<b>Total NewCo as Adjusted</b>	<b>PY Comparable Period</b>	<b>Reported % Change</b>	<b>FXN % Change</b>	<b>FX Impact</b>
<b>12 Months Ended September 30, 2017</b>													
EMERGING MARKETS	1,953	0	434	-	(33)	(2)	-	-	2,352	2,132	10.3%	12.0%	(36)
DEVELOPED MARKETS	10,140	0	3,442	-	33	(46)	(173)	(14)	13,380	12,908	3.7%	4.1%	(56)
CHINA	686	(0)	254	-	-	(1)	-	-	940	855	9.9%	14.5%	(39)

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE - EMERGING & DEVELOPED MARKETS, CHINA  
(Unaudited; Amounts in millions)

	A	B	C	D	E	F	G	H	I=A+B+C+D +E+F+G+H	J	K=(I-J)/J	L=(I-J- M)/J	M
	BDX as Reported	BD Realign BUs FN#1	Bard as Reported FN#2	Bard Realign BUs FN#3	Bard Align Region Reporting FN#4	Divestiture Adjust FN#5	Gore Royalty Classification Adjust FN#6	Interco Adjust FN#7	Total NewCo as Adjusted	PY Comparable Period	Reported % Change	FXN % Change	FX Impact
<b>3 Months Ended December 31, 2017</b>													
EMERGING MARKETS	508	0	129	-	(10)	(1)	-	-	626	551	13.6%	11.9%	9
DEVELOPED MARKETS	2,572	0	884	-	10	(12)	(46)	(3)	3,406	3,281	3.8%	2.3%	51
CHINA	180	(0)	72	-	-	(0)	-	-	252	220	14.9%	12.4%	6

**Footnote Explanations**

- 1 Represents re-alignment of certain BD products previously reported in the Medication and Procedural Solutions unit within the BD Medical Segment to the new BD Interventional Segment. For additional details, see page 2.
- 2 Represents the as-reported presentation of Bard product revenues, previously defined by disease state, aligned to BD's fiscal year and quarterly reporting cycle.
- 3 Represents the re-alignment of certain Bard products to the Medication Delivery Solutions unit (previously the Medication and Procedural Solutions unit) within the BD Medical Segment. In addition, the remaining legacy Bard products have been re-aligned to units within the new BD Interventional Segment. For additional details, see page 2.
- 4 Represents re-alignment of Bard country reporting to align to BD's existing presentation.
- 5 Represents divestitures of BD Respiratory, Simplest and Spine and the pending divestiture of BD's soft tissue core needle biopsy product line and Bard's Aspira® product line of tunneled home drainage catheters and accessories.
- 6 Amounts previously reported by Bard as revenue related to the Gore royalty have been reclassified to Other Income to reflect the future reporting classification by BD.
- 7 Amounts represent revenues recognized between BD and Bard previously recognized as 3rd party revenue, which will be considered as intercompany revenue.